MRK dividend yield: 3.25%. JEPQ dividend yield: 8.21%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. JEPQ applies JEPI's covered call strategy to Nasdaq 100 stocks, providing high monthly income with tech sector exposure. Higher growth potential than JEPI with comparable income. With $15B+ in AUM, it's rapidly becoming a favorite for growth-income hybrid investors.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
JEPQ applies JEPI's covered call strategy to Nasdaq 100 stocks, providing high monthly income with tech sector exposure. Higher growth potential than JEPI with comparable income. With $15B+ in AUM, it's rapidly becoming a favorite for growth-income hybrid investors.
Is MRK or JEPQ better for dividend income in 2026?
MRK currently offers a 3.25% yield (3.08/share/year) while JEPQ offers 8.21% (4.50/share/year). JEPQ provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs JEPQ earn per year?
With $10,000 invested today: MRK pays approximately $325/year. JEPQ pays approximately $821/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $2,477/year (JEPQ).
Does MRK or JEPQ pay monthly dividends?
MRK pays quarterly dividends. JEPQ pays monthly dividends. JEPQ pays monthly, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs JEPQ comparison by email
Save your analysis + get weekly dividend insights. Free forever.